Steroid management in giant cell arteritis

Area of Science:

• Ophthalmology
• Rheumatology
• Vascular Medicine

Background:

• Giant cell arteritis (GCA) is a medical emergency with potential for irreversible vision loss.
• Current steroid treatment protocols for acute GCA lack robust evidence.
• Ocular complications, particularly anterior ischemic optic neuropathy (AION), are a major concern in GCA.

Purpose of the Study:

• To review the effectiveness of intravenous (IV) and oral steroid treatments for GCA.
• To analyze treatment outcomes, including visual acuity changes and complications, in patients with GCA and visual loss.

Main Methods:

• Retrospective review of 100 patients with biopsy-proven GCA.
• Inclusion of 73 patients with visual loss treated at two hospitals.
• Analysis of treatment type, dosage, visual acuity response, and complications within the first week of presentation.

Main Results:

• Anterior ischemic optic neuropathy (AION) was the primary cause of visual loss in 99% of patients.
• Visual acuity improved in 29% of patients after steroid initiation.
• Intravenous steroids showed a higher rate of visual improvement (40%) compared to oral steroids (13%).

Conclusions:

• Early steroid administration in GCA can significantly improve visual acuity.
• Intravenous steroids may offer a better prognosis for vision recovery than oral steroids.
• Further prospective studies are warranted to compare IV and oral steroid efficacy in GCA.